June 6, 2025 A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions
The change process acknowledges the fundamental differences between these medications, particularly in their receptor activities and mechanisms of action
Effectiveness for Weight Loss Studies have shown that Tirzepatide leads to greater weight loss compared to Semaglutide
The concern originated from studies on people with existing kidney disease
Youre Still Early in Treatment The first few weeks may not accurately reflect your long-term results
Real-World Case Study: 220 lb Athlete on Retatrutide Baseline : 220 lbs, ~25% body fat (55 lbs fat, 165 lbs muscle) Protocol : Retatrutide 2.4 mg weekly 2,300 kcal daily, 180g protein 5x/week lifting (push-pull split) MOTS-C 5 mg daily, GHK-Cu 0.5 mg daily Duration: 16 weeks Expected results: Total weight loss: 20-22 lbs (in line with Phase 3) Fat loss: ~17-18 lbs (83% of total) Muscle loss: 2-3 lbs (17% of total) Final body composition: 203-205 lbs, 17-18% body fat, 165-167 lbs muscle Outcome : 17 lbs of pure fat loss with minimal muscle damagea physique transformation that would take 6 months of traditional dieting and produce more muscle loss